The rapid release of viral genomic sequences allows early immunoinformatics screening before experimentally curated antigen information becomes available. In this study, the glycoprotein precursor (GP) of the newly reported ANDV/Switzerland/Hu-3337/2026 orthohantavirus was evaluated as a vaccine-design target using a stepwise workflow that integrated antigenicity prediction, conserved-region screening, transmembrane topology, MHC-I and MHC-II epitope prediction, peptide-construct design, and molecular docking against representative MHC receptors. The full GP sequence was predicted as a probable antigen by VaxiJen with a score of 0.5194. Conserved regions 1-50 and 81-240 were retained as antigenic regions and were located outside the predicted membrane-spanning helices. After filtering by MHC binding score and independent VaxiJen antigenicity, two CTL epitopes (VIYEKTHCV and KVKKTVLCY) and six HTL epitopes were selected. Four multi-epitope constructs (F1-F4) were generated using AAY and GPGPG linkers. Docking showed that F4 had the strongest MHC-I docking score (-226.92), whereas F2 had the strongest MHC-II docking score (-260.14). Residue contact-map analysis further indicated that the strongest complexes were supported by hydrogen bonds, salt bridges, alkyl/aliphatic contacts, and van der Waals interactions. These findings prioritize F2 and F4 as leading candidates for further three-dimensional refinement, molecular dynamics, allergenicity/toxicity filtering, population coverage, and experimental validation.